Whittier Trust Co. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,034 shares of the medical research company’s stock after acquiring an additional 520 shares during the period. Whittier Trust Co.’s holdings in Thermo Fisher Scientific were worth $2,285,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Barrett Asset Management LLC grew its holdings in Thermo Fisher Scientific by 0.9% during the fourth quarter. Barrett Asset Management LLC now owns 102,535 shares of the medical research company’s stock worth $19,469,000 after acquiring an additional 915 shares during the period. C WorldWide Group Holding A S grew its holdings in Thermo Fisher Scientific by 1.9% during the fourth quarter. C WorldWide Group Holding A S now owns 2,277,108 shares of the medical research company’s stock worth $432,378,000 after acquiring an additional 43,368 shares during the period. KBC Group NV grew its holdings in Thermo Fisher Scientific by 97.3% during the fourth quarter. KBC Group NV now owns 295,358 shares of the medical research company’s stock worth $56,083,000 after acquiring an additional 145,687 shares during the period. Swiss National Bank grew its holdings in Thermo Fisher Scientific by 2.2% during the fourth quarter. Swiss National Bank now owns 1,476,432 shares of the medical research company’s stock worth $280,345,000 after acquiring an additional 31,800 shares during the period. Finally, Longview Partners Guernsey LTD grew its holdings in Thermo Fisher Scientific by 6.8% during the fourth quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after acquiring an additional 311,977 shares during the period. 86.11% of the stock is currently owned by hedge funds and other institutional investors.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the sale, the senior vice president now directly owns 60,471 shares in the company, valued at approximately $13,285,478.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $209.26, for a total value of $1,046,300.00. Following the sale, the chief financial officer now owns 30,741 shares of the company’s stock, valued at $6,432,861.66. The disclosure for this sale can be found here. Insiders have sold a total of 144,327 shares of company stock valued at $28,680,042 over the last 90 days. Corporate insiders own 0.49% of the company’s stock.

A number of brokerages recently weighed in on TMO. Barclays lifted their price target on Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Bank of America lifted their price target on Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. Leerink Swann reissued an “outperform” rating and issued a $239.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target on the stock in a research note on Tuesday, October 31st. Finally, Morgan Stanley lifted their price target on Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $220.50.

Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $204.51 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $151.74 and a 1 year high of $226.44. The company has a market capitalization of $80,271.26, a PE ratio of 36.52, a price-to-earnings-growth ratio of 1.47 and a beta of 1.11. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, topping the Zacks’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a return on equity of 16.01% and a net margin of 10.64%. The firm had revenue of $6.05 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same period last year, the company posted $2.41 EPS. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. equities analysts predict that Thermo Fisher Scientific Inc. will post 10.81 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Thursday, March 15th will be given a dividend of $0.17 per share. The ex-dividend date of this dividend is Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.71%.

TRADEMARK VIOLATION NOTICE: This news story was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://theolympiareport.com/2018/02/13/thermo-fisher-scientific-inc-tmo-shares-bought-by-whittier-trust-co.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.